EHA 2026: Nurix Therapeutics' CEO Arthur Sands discusses this week's big collaboration deal with Roche, and highlights the company's EHA data and broader platform
He says he believes the Roche deal is an important transaction for the entire field of degraders. Plus, discussing antibody-degrader conjugates and an update on the company's immunology programs as well.










.png)